Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Claims A First With German Lanreotide Launch

Pushes Into Complex And Value-Added Medicines With Somatuline Rival

Executive Summary

Advanz has claimed a first with a European launch of a rival to Ipsen’s Somatuline, introducing its generic lanreotide in Germany under the name Mytolac.

You may also be interested in...



Ipsen's Sales Growth Could Be Held Back By Generics And Currency In 2021

France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.  

Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval

Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.

Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel